Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organovo Holdings, Inc. - Common Stock (NQ: ONVO )

0.7451 -0.1049 (-12.34%)
Streaming Delayed Price Updated: 12:15 PM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Organovo Holdings, Inc. - Common Stock

Small-Caps Under $2 on the Move: ENVB, ONVO, TRNR, PRSO, PNPN.V Gaining Momentum
Via AB Newswire
Topics Artificial Intelligence Derivatives Intellectual Property
Exposures Artificial Intelligence Derivatives Intellectual Property
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
From Organovo, Inc.
Via GlobeNewswire
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
From Organovo, Inc.
Via GlobeNewswire
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
From Organovo, Inc.
Via GlobeNewswire
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
From Organovo, Inc.
Via GlobeNewswire
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
From Organovo, Inc.
Via GlobeNewswire
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
From Organovo, Inc.
Via GlobeNewswire
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Renowned gastrointestinal diseases conference to held in Washington, D.C. May 18-21, 2024 
From Organovo, Inc.
Via GlobeNewswire
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
From Organovo, Inc.
Via GlobeNewswire
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
From Organovo, Inc.
Via GlobeNewswire
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
From Organovo, Inc.
Via GlobeNewswire
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
From Organovo, Inc.
Via GlobeNewswire
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
From Organovo, Inc.
Via GlobeNewswire
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
From Organovo, Inc.
Via GlobeNewswire
Organovo Highlights FXR314 Combination Therapy Potential and Plan
From Organovo, Inc.
Via GlobeNewswire
Organovo to Participate in the H.C. Wainwright Global Investment Conference
From Organovo, Inc.
Via GlobeNewswire
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
From Organovo, Inc.
Via GlobeNewswire
Organovo Announces FXR Program
Lead Molecule Poised for Phase 2 in IBD 
From Organovo, Inc.
Via GlobeNewswire
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
From Organovo, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.